Genentech develops cancer drugs with Piramed
UK oncology start-up Piramed has entered into an agreement with Genentech for the research, development, and commercialization of cancer drugs that target PI 3-kinase (phosphatidylinositol-3-kinase).
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.